Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 4, 28 April 2023
Open
Access | Article
Drug Discovery and Development of Recently Approved Drugs: Tisotumab Vedotin
* Author to whom correspondence should be addressed.
Abstract
Recurrent or metastatic cervical cancer is the primary reason for dying in the female population. Although advanced research in immunization may provide a potential treatment for cervical cancer, it is still one of the usual fetal female cancers globally. Previous studies on bevacizumab and chemotherapy provided efficient treatments with a survival benefit for women, but different strategies are needed to increase the overall survival rate of this cancer. Tisotumab vedotin is an investigative and pioneering immunoglobulin-medicine combination that targets tissue factor (TF), a protein in high concentrations in various solid tumours. Tisotumab vedotin bonds to tissue factor on aimed cells and then releases monomethyl auristatin E (MMAE). In addition, Tisotumab vedotin’s direct cytotoxicity may increase nearby tumour cells’ spectator toxicity and various immune-linked effects. This paper will discuss previous studies on Tisotumab vedotin, and their data will be analyzed further. The improvement toward this treatment will be proposed as well. This paper aimed to establish a thorough understanding and further analysis of the previous clinical trials and findings on Tisotumab vedotin.
Keywords
Cervical Cancer, Tisotumab vedotin, clinical trials
References
1. McLachlan, J. et al. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. Clin. Oncol. 29, 153–160 (2017).
2. Hong, D. S. et al. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin. Cancer Res. 26, 1220–1228 (2020).
3. Boussios, S. et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Crit. Rev. Oncol. Hematol. 108, 164–174 (2016).
4. Improved Survival with Bevacizumab in Advanced Cervical Cancer - PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010094/
5. Zamorano, A. S., Wan, L., Powell, M. A. & Massad, L. S. Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits. Gynecol. Oncol. Rep. 22, 48–51 (2017).
6. Eskander, R. N. & Tewari, K. S. Targeting angiogenesis in advanced cervical cancer. Ther. Adv. Med. Oncol. 6, 280–292 (2014).
7. Seagen Inc. A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer. https://clinicaltrials.gov/ct2/show/NCT03438396 (2022).
8. de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J.-P., Arkenau, H.-T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., Ghatta, S., Slomovitz, B. M., Spicer, J. F., Yachnin, J., Ang, J. E., Mau-Sørensen, P. M., Forster, M. D., Collins, D., Dean, E., … Lassen, U. (2019). TISOTUMAB vedotin in patients with advanced or metastatic solid tumours (innovatv 201): A first-in-human, multicentre, phase 1–2 trial. The Lancet Oncology, 20(3), 383–393.
9. X, Z. et al. Expression of tissue factor in human cervical carcinoma tissue. Exp. Ther. Med. 16, (2018).
10. Tisotumab vedotin.Browsing drugs: Drugbank online. Browsing Drugs | DrugBank Online. (n.d.). Retrieved August 24, 2022, from https://go.drugbank.com/drugs
11. Breij, E. C. W., de Goeij, B. E. C. G., Verploegen, S., Schuurhuis, D. H., Amirkhosravi, A., Francis, J., Miller, V. B., Houtkamp, M., Bleeker, W. K., Satijn, D., & Parren, P. W. H. I. (2014). An antibody–drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Research, 74(4), 1214–1226.
12. Coleman, R. L., Lorusso, D., Gennigens, C., González-Martín, A., Randall, L., Cibula, D., Lund, B., Woelber, L., Pignata, S., Forget, F., Redondo, A., Vindeløv, S. D., Chen, M., Harris, J. R., Smith, M., Nicacio, L. V., Teng, M. S., Laenen, A., Rangwala, R., … Bhatia, S. (2021). Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovatv 204/GOG-3023/ENGOT-CX6): A multicentre, open-label, single-ARM, phase 2 study. The Lancet Oncology, 22(5), 609–619. https://doi.org/10.1016/s1470-2045(21)00056-5
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Biological Engineering and Medical Science (ICBioMed 2022), Part II
- ISBN (Print)
- 978-1-915371-27-0
- ISBN (Online)
- 978-1-915371-28-7
- Published Date
- 28 April 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/4/20220526
- Copyright
- 28 April 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited